Navigation Links
Medivir Interim Report, 1 January - 30 September 2010
Date:10/22/2010

commercial value of our innovative cold sore product Xerclear(R)/Xerese(R ) and have signed two further agreements in different geographic markets.

The success demonstrated with Xerclear(R) and Xerese(R) shows Medivir's ability to develop and commercialize products and collaborate with blue-chip partners.

Following the successful rights issue concluded in June 2010 we are in healthy financial position and have therefore been able to remain focused on developing our exciting portfolio of early-phase projects for infectious diseases.

Medivir is positioned uniquely among specialty pharmaceutical companies with a potential blockbuster Hepatitis C therapy in late-stage development, a marketed product, Xerclear(R)/Xerese(R), approaching international launch, a broad earlier pipeline and a solid financial position. Medivir will now remain focused on creating further shareholder value and continues to gain momentum in its strategic goal to become a profitable specialty pharmaceutical company. We look forward to sharing our exciting future news flow going forward with both our patients and our shareholders as we continue to build the growth in this business."

For the full Q3 report please visit http://www.medivir.se. For more information, please contact Rein Piir, CFO and VP, Investor Relations, mobile: +46(0)70-853-7292. Ron Long, CEO, phone: +46(0)8-5468-3113. Forthcoming financial information and calendar Financial Statement will be published on 22 February 2011. Three-month Interim Report will be published on 5 May 2011. Annual General Meeting will be held on 5 May 2011.

Additional information on Medivir's operations is available on the company's website, http://www.medivir.se.


'/>"/>
SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
(Date:12/22/2014)... and STOCKHOLM , Dec. ... (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that ... of the European Medicines Agency (EMA) has adopted a ... histolyticum) for the treatment of adult men with Peyronie,s ... at least 30 degrees at the start of therapy. ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... 25, 2014 Parker & Sons, Inc. ... service and affordable quality regarding heating, cooling and plumbing ... in 2014 by the “Queen of Clean” for impressive ... an impressive reputation over the years for providing outstanding ... range of contractor services for both homeowners and businesses. ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
(Date:12/24/2014)... 24, 2014 Dr. Vu Ho, a ... of his practice and med-spa with the addition of ... list of cosmetic treatments and services. , “Silk Peel ... skin,” says Dr. Ho. “As a result it can ... wrinkles, sun spots, discolorations or blemishes.” , Similar to ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
Breaking Medicine News(10 mins):Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3
... molecules that are responsible for controlling genes that cause ... Memorial Sloan-Kettering Cancer Center (MSKCC), appears in the January ... inhibit the activity of entire sets of genes associated ... the majority of cancer-related deaths. The new work explains ...
... PRGO ; TASE) today announced that it has ... in Barnsley, Yorkshire,United Kingdom, privately-held Galpharm is a leading ... super,markets, drug stores and pharmacies in the U.K. The ... sales annually and be accretive to earnings,in the first ...
... Court Justice Antonin Scalia, FDA Commissioner Andrew C.,von ... FDLI/FDA,Meeting in Washington, D.C., WASHINGTON, Jan. 9 ... Conference, co-sponsored with the Food and Drug,Administration, will ... and food & drug law & regulation., ...
... Trial Begins this Week in Fort Worth, Texas in an ... Toxins in the Air,Destroying a Town, Hundreds of Residents ... Birth Defects, NEW YORK, Jan. 9 The first ... a railroad tie,factory poisoned residents in the small town of ...
... a quick fix to physical and mental ailments, psychoanalysts ... about the potential benefits and drawbacks of including medication ... The Uses of Medications in Psychoanalysis: What We Know; ... psychoanalyst Glen O. Gabbard, M.D., at the American Psychoanalytic ...
... Extract Released Just in Time for the Holiday ... ... The average American gains 50%,of his yearly weight gain during the Holiday ... overweight., Metabothin ( http://www.metabothin.net ), the herbal weight loss formula,from American ...
Cached Medicine News:Health News:Molecules can block breast cancer's ability to spread 2Health News:Perrigo Acquires UK OTC Store Brand Supplier 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 2Health News:51st Food and Drug Law Institute Annual Conference Focuses on Relationship Between Scientific Advances and FDA Law & Regulation 3Health News:Worse Than Love Canal - A Town Poisoned by Corporate Greed 2Health News:Uses of medications in psychoanalysis 2Health News:Metabothin B56 with Ephedra Extract Now Available 2
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... malleable penile prostheses offer easy-to-use, low-cost options ... These implants are always rigid, but their ... in an erect or concealed position. Designed ... sexual intercourse and to not interfere with ...
... The Alpha I continues to be ... show the Alpha I to have mechanical ... years on first-time implants. ioflex material contributes ... Alpha I. Thats because Bioflex: ,Provides maximum, ...
Medicine Products: